133 related articles for article (PubMed ID: 3446223)
41. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Louie DS; Liang JP; Owyang C
Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
[TBL] [Abstract][Full Text] [Related]
42. Effect of loxiglumide, a cholecystokinin antagonist, on pancreatic polypeptide release in humans.
Meier R; Hildebrand P; Thumshirn M; Albrecht C; Studer B; Gyr K; Beglinger C
Gastroenterology; 1990 Dec; 99(6):1757-62. PubMed ID: 2227288
[TBL] [Abstract][Full Text] [Related]
43. Effects of synthetic human gastrin-releasing peptide on pancreatic exocrine secretion and release of pancreatic polypeptide in conscious rats.
Miyasaka K; Miyazaki K; Funakoshi A; Kitani K; Yajima H
Int J Pancreatol; 1989 Apr; 4(3):251-60. PubMed ID: 2760512
[TBL] [Abstract][Full Text] [Related]
44. Proglumide, a cholecystokinin antagonist, increases gastric emptying in rats.
Shillabeer G; Davison JS
Am J Physiol; 1987 Feb; 252(2 Pt 2):R353-60. PubMed ID: 3812772
[TBL] [Abstract][Full Text] [Related]
45. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.
Fried M; Erlacher U; Schwizer W; Löchner C; Koerfer J; Beglinger C; Jansen JB; Lamers CB; Harder F; Bischof-Delaloye A
Gastroenterology; 1991 Aug; 101(2):503-11. PubMed ID: 2065926
[TBL] [Abstract][Full Text] [Related]
46. In vivo comparison of inhibition with proglumide and CR-1409 of cholecystokinin-induced pressure in the biliary tract of the guinea pig.
Poston GJ; MacLellan DG; Hashimoto T; Upp JR; Townsend CM; Thompson JC
Surg Gynecol Obstet; 1990 Mar; 170(3):217-22. PubMed ID: 2305348
[TBL] [Abstract][Full Text] [Related]
47. CCK receptor antagonism by loxiglumide and gall bladder contractions in response to cholecystokinin, sham feeding and ordinary feeding in man.
Konturek JW; Konturek SJ; Kurek A; Bogdal J; Oleksy J; Rovati L
Gut; 1989 Aug; 30(8):1136-42. PubMed ID: 2767511
[TBL] [Abstract][Full Text] [Related]
48. Proglumide has access to brain and antagonizes the central satiety effect of cholecystokinin octapeptide in the dog.
Inui A; Inoue T; Sakatani N; Oya M; Morioka H; Baba S
Brain Res; 1987 Aug; 417(2):355-9. PubMed ID: 3651819
[TBL] [Abstract][Full Text] [Related]
49. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I
Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035
[TBL] [Abstract][Full Text] [Related]
50. Cholecystokinin receptor antagonism of stimulated pancreatic and gastric secretion.
Mulholland MW; Debas HT
J Surg Res; 1989 Nov; 47(5):460-4. PubMed ID: 2478762
[TBL] [Abstract][Full Text] [Related]
51. Duration of anti-cholecystokinin (CCK) action on the rat exocrine pancreas of new CCK receptor antagonist FK480 administered orally.
Moriyoshi Y; Shiratori K; Iwabe C; Watanabe S; Takeuchi T
J Gastroenterol; 1996 Apr; 31(2):249-53. PubMed ID: 8680546
[TBL] [Abstract][Full Text] [Related]
52. Effects of proglumide on pancreatic endocrine and exocrine function in healthy humans.
Funakoshi A; Nakano I; Shinozaki H; Miyazaki K; Ibayashi H
Regul Pept; 1987 Jun; 17(6):311-8. PubMed ID: 3299507
[TBL] [Abstract][Full Text] [Related]
53. Proglumide (gastrin and cholecystokinin receptor antagonist) inhibits insulin secretion in vitro.
Verspohl EJ; Wunderle G; Ammon HP; Williams JA; Goldfine ID
Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):284-7. PubMed ID: 3012373
[TBL] [Abstract][Full Text] [Related]
54. Role of endogenous secretin and cholecystokinin in intraduodenal oleic acid-induced inhibition of gastric acid secretion in rats.
Shiratori K; Watanabe S; Takeuchi T
Dig Dis Sci; 1992 Mar; 37(3):397-402. PubMed ID: 1735364
[TBL] [Abstract][Full Text] [Related]
55. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats.
Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T
Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923
[TBL] [Abstract][Full Text] [Related]
56. Structural features of various proglumide-related cholecystokinin receptor antagonists.
Jensen RT; Zhou ZC; Murphy RB; Jones SW; Setnikar I; Rovati LA; Gardner JD
Am J Physiol; 1986 Dec; 251(6 Pt 1):G839-46. PubMed ID: 2431626
[TBL] [Abstract][Full Text] [Related]
57. Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
Douglas BR; Woutersen RA; Jansen JB; de Jong AJ; Rovati LC; Lamers CB
Cancer Res; 1989 May; 49(9):2438-41. PubMed ID: 2706631
[TBL] [Abstract][Full Text] [Related]
58. Role of endogenous CCK in regulation of interdigestive pancreatic exocrine secretion in sheep (Ovis aries).
Tachibana S; Onaga T; Mineo H; Kato S
Comp Biochem Physiol A Physiol; 1995 Sep; 112(1):103-9. PubMed ID: 7553326
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion.
Tanikawa M; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Kodaira T; Hamaoka T
Arzneimittelforschung; 1993 Jan; 43(1):35-9. PubMed ID: 8447844
[TBL] [Abstract][Full Text] [Related]
60. Effect of proglumide on rat pancreatic growth.
Yamaguchi T; Tabata K; Johnson LR
Am J Physiol; 1985 Aug; 249(2 Pt 1):G294-8. PubMed ID: 2411150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
